US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 10:01:58 Source:travelViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:France hits go
Next:Biden to release 1 million barrels of gasoline in bid to lower prices at pump
You may also like
- Austrian leader lauds UK's efforts on migration and cites its plan for deportations to Rwanda
- 4 people die in Croatia when car carrying migrants hits a wall as driver attempts to flee police
- Landlord slammed after gloating about evicting their tenant
- North Carolina lawmakers push bill to ban most public mask wearing, citing crime
- US Open champ Coco Gauff urges young Americans to vote
- Ten Hag addresses Man United fans after winning last home game of season. Chelsea beats Brighton
- Meals on wheels! Inside London's amazing fine
- Farewell to British hero James Kirby: Military veteran
- Weather forecasters warn Pakistanis to stay indoors ahead of new heat wave